美股财报 | Y-mAbs Therapeutics发布Q2财报前半年累计净亏损同比缩小46.87%

同花顺iNews08-09

Y-mAbs Therapeutics(YMAB)发布Q2财报，2025财年前六月累计收入4042.90万美元，去年同期累计收入为4272.90万美元，同比减少5.38%。2025财年前六月累计净亏损843.60万美元，去年同期累计净亏损为1587.80万美元，同比缩小46.87%。本财年累计基本每股收益为-0.19美元，去年同期为-0.36美元。公司所属行业为制药。【公司信息】Y-mAbs ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2558496503?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-09 10:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2558496503","market":"us","top_or_hot":-1,"title":"美股财报 | Y-mAbs Therapeutics发布Q2财报 前半年累计净亏损同比缩小46.87%","media":"同花顺iNews","content":"<div>\n<p>Y-mAbs Therapeutics(YMAB)发布Q2财报，2025财年前六月累计收入4042.90万美元，去年同期累计收入为4272.90万美元，同比减少5.38%。2025财年前六月累计净亏损843.60万美元，去年同期累计净亏损为1587.80万美元，同比缩小46.87%。本财年累计基本每股收益为-0.19美元，去年同期为-0.36美元。公司所属行业为制药。【公司信息】Y-mAbs ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809100540a47e2a37&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股财报 | Y-mAbs Therapeutics发布Q2财报 前半年累计净亏损同比缩小46.87%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股财报 | Y-mAbs Therapeutics发布Q2财报 前半年累计净亏损同比缩小46.87%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-09 10:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809100540a47e2a37&s=b><strong>同花顺iNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Y-mAbs Therapeutics(YMAB)发布Q2财报，2025财年前六月累计收入4042.90万美元，去年同期累计收入为4272.90万美元，同比减少5.38%。2025财年前六月累计净亏损843.60万美元，去年同期累计净亏损为1587.80万美元，同比缩小46.87%。本财年累计基本每股收益为-0.19美元，去年同期为-0.36美元。公司所属行业为制药。【公司信息】Y-mAbs ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809100540a47e2a37&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YMAB","symbol_name":"Y-mAbs Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809100540a47e2a37&s=b","article_id":"2558496503","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809100540a47e2a37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2558496503","pubTimestamp":1754704810,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Y-mAbs Therapeutics发布Q2财报，2025财年前六月累计收入4042.90万美元，去年同期累计收入为4272.90万美元，同比减少5.38%。Y-mAbs Therapeutics, Inc.于2015年4月30日根据特拉华州法律注册成立。该公司是一家商业化阶段的生物制药公司，专注于新型放射免疫疗法和基于抗体的治疗产品的开发和商业化，用于治疗癌症。该公司正在利用专有的放射免疫疗法和抗体平台和专业知识来开发广泛的创新药物组合。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"YMAB":"Y-mAbs Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"U.S. stock financial report | Y-mAbs Therapeutics releases Q2 financial report, cumulative net loss in the first half of the year narrowed by 46.87% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YMAB":0.9,"LENZ":1},"content_text":"Y-mAbs Therapeutics(YMAB)发布Q2财报，2025财年前六月累计收入4042.90万美元，去年同期累计收入为4272.90万美元，同比减少5.38%。2025财年前六月累计净亏损843.60万美元，去年同期累计净亏损为1587.80万美元，同比缩小46.87%。本财年累计基本每股收益为-0.19美元，去年同期为-0.36美元。公司所属行业为制药。【公司信息】Y-mAbs Therapeutics, Inc.于2015年4月30日根据特拉华州法律注册成立。该公司是一家商业化阶段的生物制药公司，专注于新型放射免疫疗法和基于抗体的治疗产品的开发和商业化，用于治疗癌症。该公司正在利用专有的放射免疫疗法和抗体平台和专业知识来开发广泛的创新药物组合。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2558496503","isCrawlerRequest":true}

美股财报 | Y-mAbs Therapeutics发布Q2财报 前半年累计净亏损同比缩小46.87%

精彩评论

美股财报 | Y-mAbs Therapeutics发布Q2财报前半年累计净亏损同比缩小46.87%